NPPB and hydrops fetalis: The secondary outcomes include change from baseline to week 52 in log-formatted NT-proBNP, time to the first cardiovascular events such as cardiovascular death, hospitalization, or worsening of HF, adverse effects, and pharmacokinetic parameters for tablet and oral liquid formulations.